Abstract
Background It is very common that symptoms do not improve or even worsen after intravenous thrombolysis (IVT) in acute ischemic stroke. However, it remains unknown whether early administration of tirofiban after IVT may improve clinical outcomes.
Objective This trial aims to assess the efficacy and safety of early administration of tirofiban after intravenous thrombolysis with Tenecteplase in acute ischemic stroke within 24 hours of symptom onset.
Methods and design The INSTANT trial is an investigator-initiated, randomized, placebo-controlled, double-blind, multicenter trial. Up to 310 patients with acute non-large/medium-sized vascular occlusion and non-atrial fibrillation stroke who are treated with intravenous tenecteplase will be consecutively randomized to intravenous tirofiban or placebo in a 1:1 ratio over two years across 50 intravenous thrombolysis-capable stroke centers in China. Subjects will be treated with intravenous tirofiban or placebo at a dose of 0.3 μg per kilogram of body weight per minute for 30 minutes, followed by a continuous infusion of 0.075 μg per kilogram per minute for up to 47.5 hours.
Outcomes The primary efficacy outcome is the proportion of patients with excellent functional outcomes (defined as a score of 0-1 on the modified Rankin scale (mRS)) at 90 days. The secondary outcome is the proportion of patients achieving functional independence, defined as a mRS score of 0-2 at 90 days. Safety outcomes include symptomatic intracranial hemorrhage within 48 hours and mortality at 90 days.
Discussion This randomized, double-blind, placebo-controlled trial will provide data regarding the role of early antiplatelet therapy with intravenous tirofiban after IVT.
Trial registry number ChiCTR2300074368 (www.chictr.org.cn).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Trial registry number: ChiCTR2300074368 (www.chictr.org.cn)
Funding Statement
This clinical trial is sponsored by: (1) Lunan Pharmaceutical Group Co., Ltd., China, (2) Ganzhou People's Hospital Talent Training Program (No. 2023108). The sponsors had no role in the study design, data collection, analysis and interpretation, and in drafting and submitting this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Fan Zhang, MD, Minghui Xiao, MD, and Cong Zhang, MD are co-first authors.
Data Availability
not applicable
Non-standard Abbreviations and Acronyms
- IVT
- intravenous thrombolysis
- mRS
- modified Rankin scale
- AIS
- acute ischemic stroke
- END
- early neurological deterioration
- sICH
- symptomatic intracranial hemorrhage
- GPI
- glycoprotein IIb/IIIa inhibitor
- NIHSS
- National Institutes of Health Stroke Scale
